Elevation Oncology: Mid-2024 EO-3021 Data Could Get Ball Rolling [Seeking Alpha]
Elevation Oncology, Inc. - Common stock (ELEV)
Company Research
Source: Seeking Alpha
HER3-ADC is another ADC being developed in the pipeline for the treatment of patients with HER3-expressning solid tumors; It has been shown that up to 42% of tumors express HER3. Nomination of ADC candidate for HER3-ADC clinical program expected in the 2nd half of 2024. Plans, to advance EO-3021 in combination with another cancer drug to treat patients with advanced solid tumors, expected in the 1st half of 2024. This idea was discussed in more depth with members of my private investing community, Biotech Analysis Central. Learn More » Elevation Oncology, Inc. NASDAQ: ELEV ) is gearing up to report data from its phase 1 study to treat patients with advanced solid tumors, using its drug EO-3021, in mid-Q3 of 2024. This will be a major inflection point for investors to keep an eye on because it will be possible that it could establish proof-of-concept in being able to treat these patients. Specifically, it is targeting advanced solid tumor types such as: Gastric, gastroesophage
Show less
Read more
Impact Snapshot
Event Time:
ELEV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ELEV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ELEV alerts
High impacting Elevation Oncology, Inc. - Common stock news events
Weekly update
A roundup of the hottest topics
ELEV
News
- Elevation Oncology, Inc. (NASDAQ: ELEV) is now covered by analysts at Stephens. They set an "overweight" rating and a $8.00 price target on the stock.MarketBeat
- Elevation Oncology, Inc. (NASDAQ: ELEV) is now covered by analysts at Stephens. They set an "overweight" rating and a $8.00 price target on the stock.MarketBeat
- Elevation Oncology to Present at the Citizens JMP Life Sciences Conference [Yahoo! Finance]Yahoo! Finance
- Elevation Oncology to Present at the Citizens JMP Life Sciences ConferencePR Newswire
- Elevation Oncology, Inc. (NASDAQ: ELEV) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $8.00 price target on the stock.MarketBeat
ELEV
Sec Filings
- 5/17/24 - Form 4
- 5/10/24 - Form EFFECT
- 5/9/24 - Form 424B3
- ELEV's page on the SEC website